Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CATX Perspective Therapeutics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: CATX
Price (delayed)
$2.46
Market cap
$182.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.25
Enterprise value
$142.01M
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
Highlights
Perspective Therapeutics's EPS has increased by 35% YoY
The company's quick ratio rose by 34% QoQ and by 33% YoY
The debt has increased by 33% year-on-year but it has declined by 6% since the previous quarter
CATX's equity is up by 24% year-on-year but it is down by 2.1% since the previous quarter
The net income has contracted by 46% YoY and by 7% from the previous quarter
The revenue has declined by 3.6% year-on-year
Key stats
What are the main financial stats of CATX
Market
Valuations
Earnings
Shares outstanding
74.23M
Market cap
$182.6M
Enterprise value
$142.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
121
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
96.54
Revenue
$1.47M
Gross profit
$1.47M
Operating income
-$99.71M
Net income
-$85.17M
EBIT
-$87.12M
EBITDA
-$84.47M
Free cash flow
-$103.39M
Per share
Balance sheet
Liquidity
EPS
-$1.25
EPS diluted
-$1.25
Free cash flow per share
-$1.43
Book value per share
$3.84
Revenue per share
$0.02
TBVPS
$3.86
Total assets
$329.35M
Total liabilities
$44.7M
Debt
$3.82M
Equity
$284.65M
Working capital
$203.06M
Debt to equity
0.01
Current ratio
17.02
Quick ratio
16.7
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
-5,742.2%
Gross margin
100%
Net margin
-5,790.1%
Operating margin
-6,778.6%
Return on assets
-23.5%
Return on equity
-27.4%
Return on invested capital
-62.1%
Return on capital employed
-27.5%
Return on sales
-5,922.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CATX stock price
How has the Perspective Therapeutics stock price performed over time
Intraday
-13.07%
1 week
13.89%
1 month
28.13%
1 year
-84.53%
YTD
-22.88%
QTD
15.49%
Financial performance
How have Perspective Therapeutics's revenue and profit performed over time
Revenue
$1.47M
Gross profit
$1.47M
Operating income
-$99.71M
Net income
-$85.17M
Gross margin
100%
Net margin
-5,790.1%
CATX's operating margin has dropped by 134% year-on-year and by 8% since the previous quarter
The operating income has plunged by 126% YoY and by 10% from the previous quarter
The net margin has dropped by 51% year-on-year and by 6% since the previous quarter
The net income has contracted by 46% YoY and by 7% from the previous quarter
Price vs fundamentals
How does CATX's price correlate with its fundamentals
Growth
What is Perspective Therapeutics's growth rate over time
Valuation
What is Perspective Therapeutics stock price valuation
P/E
N/A
P/B
0.64
P/S
121
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
96.54
Perspective Therapeutics's EPS has increased by 35% YoY
CATX's P/B is 68% below its 5-year quarterly average of 2.0 and 57% below its last 4 quarters average of 1.5
CATX's equity is up by 24% year-on-year but it is down by 2.1% since the previous quarter
CATX's P/S is 63% below its last 4 quarters average of 326.4
The revenue has declined by 3.6% year-on-year
Efficiency
How efficient is Perspective Therapeutics business performance
Perspective Therapeutics's ROS has plunged by 79% YoY and by 6% from the previous quarter
CATX's ROIC has soared by 78% YoY and by 26% QoQ
The ROE has grown by 40% YoY but it has contracted by 3% from the previous quarter
The ROA has increased by 39% YoY but it has decreased by 3.5% from the previous quarter
Dividends
What is CATX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CATX.
Financial health
How did Perspective Therapeutics financials performed over time
The company's quick ratio rose by 34% QoQ and by 33% YoY
The current ratio rose by 34% since the previous quarter and by 31% year-on-year
The debt is 99% smaller than the equity
The debt has increased by 33% year-on-year but it has declined by 6% since the previous quarter
CATX's equity is up by 24% year-on-year but it is down by 2.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.